echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Treatment of AML "first-in-class" monoclonal antibodies initiates Phase 1 clinical trials.

    Treatment of AML "first-in-class" monoclonal antibodies initiates Phase 1 clinical trials.

    • Last Update: 2020-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Immune-Onc Therapeutics, which specializes in the development of the "first-in-class" biological therapy drug, announced that IO-202, a research-based therapy developed by the company targeting white blood cell immunoglobulin-like subjects B4 (LILRB4, also known as ILT3), has completed the first patient administration in Phase 1 clinical studies.
    Phase 1 clinical dose increment and amplification trial will assess the efficacy of IO-202 in treating patients with acute myeloid leukemia (AML) with monocyte differentiation and patients with chronic granulocytic leukemia (CMML).
    AML is the most common acute leukemia in adults and is characterized by the proliferation of abnormal myelin cells (a type of white blood cell) in the bone marrow.
    progress has been made in treatment, less than 30 per cent of AML patients are still alive within five years of their first diagnosis.
    ISML is a cancer that starts in the bone marrow to make blood cells and invade the blood.
    rare, with about 1,100 cases a year in the United States.
    IO-202 is a "first-in-class" monoclonal antibody that blocks the signaling of the immunosuppressive liLRB4.
    October 2018, Immune-Onc and the University of Texas published a groundbreaking study (DOI:10.1038/s41586-018-0615-z) that sheds light on the role of LILRB4 in AML immunosuppression and tumor immersion.
    Preclinical studies have shown that IO-202 inhibits leukemia cell immersion by converting the "don't kill me" signal into a "kill me" signal, activating T cells to kill AML cells, and by converting the "don't find me" signal into a "find me" signal.
    press release that this is the first T-cell activator to treat AML.
    In addition to IO-202, Immune-Onc's research and development pipeline includes IO-108, an anti-LAIR1 antibody, and a variety of unexclosed in-study therapies targeting LILRB2 (also known as ILT4), as well as a variety of unreclosed tumors of solid tumors and hematoses.
    Immune-Onc's research and development pipeline (Photo: Immune-Onc's official website) References: immune-Onc Therapeutics Announcs First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for The Treatment of Acute Myeloid Leukemia. Retrieved September 21, 2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.